胰高血糖素样肽1受体激动剂相关的消化系统不良反应综述  

Adverse reactions of the digestive system caused by glucagon-like peptide-1 receptor agonists

作　　者：卢春晓 路长飞 张华琦 刘文文 崔小康[2] LU Chunxiao;LU Changfei;ZHANG Huaqi;LIU Wenwen;CUI Xiaokang(Cheeloo College of Medicine,Shandong University,Jinan 250012,China;Shandong Center for Adverse Drug Reaction Monitoring,Jinan 250013,China)

机构地区：[1]山东大学齐鲁医学院,济南250012 [2]山东省药品不良反应监测中心,济南250013

出　　处：《中国药房》2024年第12期1539-1544,共6页China Pharmacy

摘　　要：胰高血糖素样肽1受体激动剂(GLP-1RAs)近年来广泛应用于糖尿病和肥胖人群,同时也引起了一系列不良反应,其中最重要的是消化系统不良反应。GLP-1RAs相关的消化系统不良反应涉及胃肠道、胰腺和胆道,其中恶心、呕吐、便秘、腹泻发生率较高,是导致患者停药的主要原因。胰腺和胆道系统疾病的发病率较低,但尚无研究证据可排除其与GLP-1RAs的关联。替尔泊肽上市较晚,其安全性尚缺乏足够的真实世界数据。医护人员应对患者采用积极的饮食指导策略,并加强用药教育,以帮助患者积极预防、科学应对GLP-1RAs相关的消化系统不良反应的发生。Glucagon-like peptide-1 receptor agonists(GLP-1RAs) have been widely used in diabetes and obese people in recent years,and they have also caused a series of adverse reactions,the most important of which is digestive system-related adverse reactions.The adverse reactions of the digestive system associated with GLP-1RAs involve the gastrointestinal,pancreatic,and biliary tracts;among them,nausea,vomiting,constipation,and diarrhea are the most common adverse reactions,which are the main reasons for drug withdrawal.The incidence of pancreatic and biliary system diseases is low,but there is no research evidence to exclude their association with GLP-1RAs.Tirzepatide appears on the market relatively late,and its safety still lacks sufficient real-world data.Medical staff should adopt active dietary guidance strategies for patients and strengthen medication education to help patients actively prevent and scientifically respond to adverse reactions in the digestive system.

关 键 词：胰高血糖素样肽1受体激动剂 消化系统 不良反应 

分 类 号：R977.15[医药卫生—药品] R587.1[医药卫生—药学]